分子对接和在中预测分析Momordica charantia和Miglitol之间的潜在草药相互作用
Ponnusankar S1, Preethi R1, Lithish Kumar Mk1
1Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, IND.
Cureus
|June 26, 2025
概括
莫莫迪卡 (Momordica charantia) (苦瓜) 的化合物,尤其是查兰丁,可能会增加米格利托尔.
科学领域:
- 药理学和植物化学
- 计算机化药物发现技术
背景情况:
- 2型糖尿病 (T2DM) 是一种慢性代谢障碍,以高血糖症为标志.
- 阿尔法葡萄糖酶抑制剂,如米格利托尔,通过延迟碳水化合物吸收来管理T2DM.
- 蜜瓜 (Momordica charantia) 具有低血糖特性,但其与抗糖尿病药物的相互作用尚不清楚.
研究的目的:
- 为了研究Momordica charantia植物成分和米格利托尔的酶性标之间的分子相互作用.
- 使用in silico方法评估潜在的草药相互作用.
主要方法:
- 植物化学查发现了Momordica charantia中的18种生物活性化合物,它们符合Lipinski的五项规则.
- 使用AutoDock工具进行了分子对接,以评估这些化合物与关键碳水化合物代谢酶 (GAA,GANAB,GANC,MGAM,AMY2A) 的结合亲和力.
- 使用PyMOL和LigPlot+可视化结合相互作用以评估分子稳定性.
主要成果:
- 沙兰丁在所有向酶中表现出最高的结合亲和力,特别是与中性α-葡萄糖酶AB (-12.4 kcal/mol) 和马尔塔酶-葡萄糖胺酶 (-12.6 kcal/mol).
- 其他化合物,如奎尔塞丁,卢托林和凯姆菲罗尔显示中等到高的结合亲和力,表明潜在的协同效应.
- 在charantin和关键酶残留物之间观察到稳定的结合和疏水相互作用.
结论:
- 莫莫迪卡·查兰蒂亚的植物成分,特别是查兰丁,可以通过抑制碳水化合物消化酶来增强米格利托尔的降糖效应.
- 有可能提高疗效,但也存在过度抑制导致食后低血糖症的风险.
- 进一步的体外和体内研究至关重要,以验证这些发现,并评估联合使用的临床影响.
关键词:
的α-葡萄糖酶抑制剂.查伦丁 查伦丁 查伦丁糖尿病 糖尿病患者 糖尿病患者草药与药物的相互作用分子对接的分子对接.莫莫迪卡·查兰蒂亚 (Momordica charantia) 是一个的动物.更多相关视频
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.4K
05:08Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
Published on: July 8, 2025
383
相关概念视频
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
276
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
276
01:29Drug-Receptor Interactions
6.1K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
6.1K